pathalys.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $146.75MM
Pathalys Pharma is a biopharmaceutical company with a mission to treat kidney disease with therapeutic technology. Aiming to help patients who have chronic kidney disease by meeting their unmet needs, the company created a calcimimetic drug called upacicalcet with the hopes of it being more tolerable for kidney disease patients. Patlalys Pharma was founded in 2021 by Ashwin Ram, BT Slingsby, Jay P. Shepard, Mahesh Krishnan, and Takeshi Takahashi and is headquartered in Raleigh, North Carolina.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/20/2024 | Series B | $105MM | $xx.xx | $284.99MM | Catalys Pacific, DaVita, Japan Post Investment, Jp Morgan, Kb Investment, Marshall Wace, Samsara Biocapital, Tcg Crossover Management | |
Price per Share
$xx.xx
Shares Outstanding
9,678,064
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.5%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Catalys Pacific, DaVita, Japan Post Investment, Jp Morgan, Kb Investment, Marshall Wace, Samsara Biocapital, Tcg Crossover Management
|
||||||
01/18/2023 | Series A-1 | $30MM | $xx.xx | $111.71MM | Abingworth, Catalys Pacific, DaVita, Orbimed, The Carlyle Group | |
Price per Share
$xx.xx
Shares Outstanding
3,090,996
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Catalys Pacific, DaVita, Orbimed, The Carlyle Group
|
||||||
06/22/2021 | Series A-2 | $11.75MM | $xx.xx | $39.16MM | Catalys Pacific, DaVita | |
Price per Share
$xx.xx
Shares Outstanding
1,513,076
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalys Pacific, DaVita
|